28.52
-0.19 (-0.66%)
| 前收盘价格 | 28.71 |
| 收盘价格 | 28.13 |
| 成交量 | 1,920,400 |
| 平均成交量 (3个月) | 1,675,950 |
| 市值 | 4,533,681,664 |
| 预期市盈率 (P/E Forward) | 90.91 |
| 价格/销量 (P/S) | 5.78 |
| 股市价格/股市净资产 (P/B) | 7.37 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 - 9 May 2025 |
| 营业毛利率 | -64.37% |
| 营业利益率 (TTM) | -48.91% |
| 稀释每股收益 (EPS TTM) | -3.04 |
| 季度收入增长率 (YOY) | -30.20% |
| 总债务/股东权益 (D/E MRQ) | 332.93% |
| 流动比率 (MRQ) | 8.47 |
| 营业现金流 (OCF TTM) | -500.95 M |
| 杠杆自由现金流 (LFCF TTM) | -352.83 M |
| 资产报酬率 (ROA TTM) | -9.91% |
| 股东权益报酬率 (ROE TTM) | -93.10% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Ionis Pharmaceuticals, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.75 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.83% |
| 机构持股比例 | 105.07% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tweedy, Browne Co Llc | 31 Dec 2024 | 3,248,863 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 70.00 (RBC Capital, 145.44%) | 购买 |
| 中 | 52.50 (84.08%) | |
| 低 | 39.00 (Redburn Atlantic, 36.75%) | 保留 |
| 平均值 | 53.83 (88.75%) | |
| 总计 | 3 购买, 3 保留 | |
| 平均价格@调整类型 | 32.40 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Redburn Atlantic | 31 Mar 2025 | 39.00 (36.75%) | 保留 | 30.17 |
| JP Morgan | 24 Mar 2025 | 45.00 (57.78%) | 保留 | 33.45 |
| 11 Mar 2025 | 47.00 (64.80%) | 保留 | 33.03 | |
| BMO Capital | 20 Feb 2025 | 45.00 (57.78%) | 保留 | 32.69 |
| Citigroup | 20 Feb 2025 | 64.00 (124.40%) | 购买 | 32.69 |
| Needham | 20 Feb 2025 | 60.00 (110.38%) | 购买 | 32.69 |
| RBC Capital | 20 Feb 2025 | 70.00 (145.44%) | 购买 | 32.69 |
| 15 Jan 2025 | 70.00 (145.44%) | 购买 | 33.21 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合